Recombinant Human DEC-205/CD205 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 10205-DE

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
10205-DE-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

O60449.3

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all DEC-205/CD205 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human DEC-205/CD205 protein
Human DEC-205/CD205
(Ser28-Asp1666)
Accession # O060449.3		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser28

Predicted Molecular Mass

215 kDa

SDS-PAGE

200-250 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human CD302/CLEC13A Fc Chimera (Catalog # 10203-CL) is immobilized at 5 µg/mL (100 µL/well), Recombinant Human DEC-205/CD205 Fc Chimera (Catalog # 10205-DE) binds with an ED50 of 4-28 μg/mL.

Scientific Data Images for Recombinant Human DEC-205/CD205 Fc Chimera Protein, CF

When Recombinant CD302/CLEC13A Fc Chimera (10203-CL) is immobilized at 5 µg/mL, 100 µL/well, Recombinant Human DEC-205/CD205 Fc Chimera (Catalog # 10205-DE) binds with an ED50 of 4-28 µg/mL.

Formulation, Preparation and Storage

10205-DE
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: DEC-205/CD205

DEC-205, also known as CD205 and lymphocyte antigen 75 (Ly75), is a type I transmembrane protein that is part of the macrophage mannose receptor (MMR) family of C-type lectins (1). Both the human and mouse proteins share a similar extracellular (ECD) structure consisting of a cysteine rich N-terminal domain, a fibronectin type II domain, and multiple C-type lectin-like domains (1, 2). The mature ECD of human DEC-205 shares 68% amino acid (aa) identity with mouse DEC‑205. DEC‑205 is primarily expressed on dendritic cells (DC) of lymphoid tissues and at lower levels on macrophages and T cells (3, 4). DEC-205 functions as an endocytic receptor for antigens (3, 4). DEC-205 was shown to be a a cell surface receptor for CpG-oligonucleotides (ODN), as mice deficient in DEC-205 have impaired DC and B-cell maturation (5). DEC-205 expressing Kupffer stellate macrophage cells in the liver responded to CpG-ODN and subsequently released cytokines to promote NKT cell activation, leading to liver damage (6). DEC-205 also recognizes apoptotic and necrotic cells by binding to keratin in a pH-dependent fashion, leading to either immune activation or tolerance in the absence or presence of inflammatory stimuli (7, 8). DEC-205 positive macrophages in the human gastric mucosa were shown to mediate local and systemic immune responses to H. pylori infection, which affects systemic immunity (9). DEC-205 was also found to exist as an intergenic splice variant able to form a fusion protein with CD302 in Hodgkin's lymphoma cell lines (10). The DEC-205/CD302 fusion protein was also found to be expressed by mature dendritic cells which altered endocytic capacity of DEC-205, although the wild-type single gene transcripts were the dominant isoforms expressed (11). DEC-205 has been widely used in immune therapies for vaccine generation. Targeting of antigens to DEC-205 resulted in enhanced antigen presentation by DC. In combination with adjuvants, proteins coupled to antibodies against DEC-205 induced strong pathogen-specific immune responses, while without additional adjuvant tolerance could be induced (12).

References

  1. Butler, M. et al. (2007) Immunology. 120:362.
  2. Jiang, W. et al. (1995) Nature. 375:151.
  3. Bonifaz, L. et al. (2002) Jour. Exp. Med. 196:1627.
  4. Shrimpton, R. et al. (2009) Mol. Immunol. 46:1229.
  5. Lahoud MH. et al. (2018) Proc Natl Acad Sci U.S.A. 109:16270.
  6. Hou X. et al. (2017) Cell Mol Immunol. 14:675.
  7. Cao L. et al. (2016) Proc Natl Acad Sci U.S.A. 113:13438.
  8. Hawiger D. et al. (2001) J Exp Med. 194:769.
  9. Kita M. et al. (2018) Oncotarget. 9:15828.
  10. Kato, M. et al. (2003) J Biol Chem. 278:34035.
  11. Butler M. et al. (2017) J. Immunol. 120:362.
  12. Niezold T. et al. (2015) Immunology. 145:519.

Alternate Names

CD205, DEC205, Ly75

Entrez Gene IDs

4065 (Human); 17076 (Mouse)

Gene Symbol

LY75

UniProt

O60449.3

Additional DEC-205/CD205 Products

Product Documents for Recombinant Human DEC-205/CD205 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human DEC-205/CD205 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.